Drugs / STSA-1005
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05559125 | Nov 2022 → Mar 2024 | — | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Terminated | No outcome recorded |
| Phase 1 | NCT05085197 | Oct 2021 → Apr 2022 | — | Staidson Biopharma Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STSA-1005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05559125 ↗ |
| Route | Intravenous | “Intravenous injection” NCT05085197 ↗ |